EP1351734A2 - Dry powder inhaler - Google Patents

Dry powder inhaler

Info

Publication number
EP1351734A2
EP1351734A2 EP01992208A EP01992208A EP1351734A2 EP 1351734 A2 EP1351734 A2 EP 1351734A2 EP 01992208 A EP01992208 A EP 01992208A EP 01992208 A EP01992208 A EP 01992208A EP 1351734 A2 EP1351734 A2 EP 1351734A2
Authority
EP
European Patent Office
Prior art keywords
dose
sheet
pressurized air
substrate
trough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01992208A
Other languages
German (de)
French (fr)
Other versions
EP1351734B1 (en
Inventor
Perry Genova
Warren Jewett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Life Sciences Inc
Original Assignee
IEP Pharmaceutical Devices LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IEP Pharmaceutical Devices LLC filed Critical IEP Pharmaceutical Devices LLC
Publication of EP1351734A2 publication Critical patent/EP1351734A2/en
Application granted granted Critical
Publication of EP1351734B1 publication Critical patent/EP1351734B1/en
Priority to CY20081100056T priority Critical patent/CY1108525T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B17/00—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
    • B05B17/04—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
    • B05B17/06—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods using ultrasonic or other kinds of vibrations
    • B05B17/0692—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods using ultrasonic or other kinds of vibrations generated by a fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

A dry powder inhaler having a housing, at least one single dose storage chamber (17) able to contain a single unit dose, a discharge path (20) adjacent the storage chamber (17), and a flexible and bendable seal plate (14) closing the discharge path (20). When an air flow under pressure is applied to the top of the dose, the top seal is broken and the dose is driven against the seal plate (14) which deflects away, allowing the powder of the dose to be driven into and along the discharge path (20). The air flow causes the seal plate (14) (in the discharge path) to vibrate, which acts to break up the dose into particles of preferred size, as the dose is carried along with the air flow and delivered to a patient.

Description

DRY POWDER INHALER
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a medicament inhaler, and more particularly to a dry powder medicament inhaler operable with a source of pressurized air to produce a plume of dry powder particles .
2. Brief Description of the Prior Art
Single unit dose dry powder inhaler devices are known, including some which contain multiple chambers and a selector element for releasing a dose from one chamber at a time- Relevant aspects in the designs of these devices include: establishing the correct dosage size in the device; preserving such dose from humidity and other deleterious environment elements; and delivery of the dose in a preferred particulate size within the discharge air flow.
Stated otherwise, the concerns are charging (filling) the device and storage, release, and delivery of the dose. The stored powder is, by necessity, compacted into a very small volume in an essentially solid state capsule. One of the prominent challenges encountered in design of these systems has been the breakup, or deagglomeration, of the aggregate powder dose into a plume of fine particles which are well disbursed in the air flow. Several such devices have been developed which use a variety of methods to accomplish this end. Patent 5,694,920 describes an inhalation device. Powdered medicament is stored in a blister well that is carried in a roll housed in a cartridge. Once the blister well is opened, a vibrator deaggregates the powder in the well and keeps the powder in a fluidized state. An electrostatic plate attracts smaller particles of the powder towards the plate, where they are introduced into an air stream and carried toward a mouthpiece.
Patent 6,026,809 describes an inhalation device that utilizes vibration to facilitate suspension of a powder in a gas. A piezoelectic vibrator is used to vibrate the powder, thereby deaggregating the powder for optimal suspension in an air stream. A controller is provided for controlling the supply of actuating electricity to the vibrator.
Patent 5,033,463 describes a multi-dose inhaler for medicaments in powder form. The powder is stored in a container in the inhaler. A certain quantity of powder is withdrawn from the container and conveyed to a dispensing position by a cup. A plunger moves the powder from the cup to a mixing unit. Inhalation causes an impeller in the mixing unit to rotate, thereby mixing air and powder before they enter a user's mouth or nose. Vibrations may be used to facilitate dropping the powder from the container to the cup. Patent 6,006,747 describes a dry powder inhaler. The inhaler includes a housing, a cartridge containing medicine supported on the housing, a lid pivotally mounted on the housing, and a mixing chamber. An impeller within the mixing chamber mixes air and the drug before they are inhaled into a patient's lungs.
Patent 5,918,594 describes an inhaling device capable of breaking down aggregates of powdered medicament to provide particles within the respiratory range. A magazine contains a dose. A deagglomerating device is disposed in the air flow path of the dose. The deagglomerating device is made of opposing surfaces oriented obliquely to a longitudinal direction of the air flow path. When a patient inhales on a mouthpiece, the dose is drawn through the deagglomerating device.
Patent 6,003,512 describes an apparatus for aerosolizing and dispensing powders. A dose is placed into a chamber for mixing with pressurized air to break up large particles. The dose may be supplied at each administration, or the apparatus may contain a dose reservoir from which individual doses are supplied to the chamber. The dose mixture is moved through an ejecting conduit and into an exit nozzle. The exit nozzle has a , sudden increase in diameter to break the pressurized agglomerates into a fine aerosol. Patent 6,029,662 describes a compressed air powder inhaler. Powder is stored in a magazine. Powder from the magazine is mixed with compressed air from an air chamber. The powder is fragmented by the flow of air and then by passing through a grille. The release of the compressed air is triggered by a patient sucking on a mouthpiece. SUMMARY OF THE INVENTION
The present invention is a dry powder inhaler. The inhaler comprises four components: an exit channel, a vibrating means, a dose storage substrate and an air inlet substrate. These four components are stacked together to form the dry powder inhaler. The exit channel is a depression defined in the top surface of the exit channel substrate. The exit channel substrate may have an exit channel per stored dose, or a single exit channel shared by all stored doses. The dose storage substrate has either one, or a plurality of holes, into which a metered dose is stored. From 1 to 350 doses may be individually stored in the dose storage substrate. A vibrating material is placed between the exit channel substrate and the dose storage substrate. An air inlet substrate is positioned above the dose storage substrate. The air inlet substrate may have an air inlet per stored dose, or a single air inlet shared by all the stored doses. A small charge of pressurized air is supplied through the air inlet to the stored dose. The vibrating material deforms due to the air pressure. The powder then exits the inhaler along a trough defined by depression of the vibrating substrate into the exit channel of the exit channel substrate. Air pressure creates a standing wave in the vibrating material that serves to meter the flow of powder from the storage hole, and to deagglomerate and fluidize the stored powder in the air flow.
The present invention overcomes some disadvantages found in prior art inhaler devices, by reducing powder particle size, reducing the occurrence of larger, agglomerated particles, and/or rendering the particles in the flow to be more uniform in size. Furthermore, the present invention accomplishes these ends in an effective, yet simpler and less costly manner when compared to other designs currently available.
BRIEF DESCRIPTION OF THE DRAWINGS
Thus by the present invention its objects and advantages will be realized, the description of which should be taken in conjunction with the drawings wherein:
Figure 1 is a schematic drawing in perspective view of a simplified embodiment of the new dry powder medicament inhaler.
Figure 2 is a top planar view of the simplified embodiment of Figure 1.
Figure 2A is a sectional view thereof, taken along line 2A-2A' of Figure 2, showing the inhaler before activation.
Figure 2B is similar to Figure 2A, but shows the inhaler during activation.
Figure 2C is a front elevation view of Figure 1 before activation. Figure 2D is similar to Figure 2C, but shows the inhaler during activation.
Figure 3 is a schematic drawing, in perspective, showing an exploded view of a second embodiment of the new inhaler. Figure 4 is a fragmentary and enlarged view of the exit channel substrate of Figure 3. Figure 5 is a schematic perspective view of the inhaler of Figure 3, showing the alignment of the exit channel, dose storage chamber and air inlet channel. Figure 6 is a schematic drawing, in perspective, showing an exploded view of a third embodiment of the new inhaler.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Dose storage and deagglo eration are critical elements of unit dose dry powder inhaler devices. Combining the storage and deagglomeration elements into a single component, which accommodates both functions is desirable from a device engineering perspective, provided the powder is well protected from ambient conditions - particularly humidity - and achieves performance targets for drug delivery through the device. Metering of a dry powder can be most accurately and cost effectively achieved in a factory setting. The dry powder is metered in a factory environment directly into the storage/deagglomeration device described here. This device, when combined with supplemental energy such as pressurized air, produces a plume of dry powder with particle sizes in the respirable range. The invention includes four basic components, namely, a bottom substrate
'defining therein an exit channel, above that a sheet of vibrating material, above that a dose storage substrate, and above that an air inlet substrate.
Turning now more particularly to the drawings, Figure 1 shows schematically a simplified embodiment 10, of the new inhaler, comprising the bottom or exit channel substrate 12, the vibrating sheet substrate 14, the dose storage substrate 16, and the air inlet substrate 18. At the front is an exit discharge opening 20, and at the top is an inlet opening 22, for pressurized air. The exit channel substrate, dose storage substrate and air inlet substrate may be fabricated from any material suitable for that purpose, including a metal such as aluminum, or a plastic, such as ABS, polypropylene, polyethylene, etc.
The exit channel substrate is a base including at least one sloped exit channel, which is tapered so that it is shallow at its beginning or inlet and deeper at its exit opening. In the preferred embodiment, the channel is situated in a top surface of this base or exit channel substrate, the channel defining a grooved passageway in the solid substrate and being open at the top. The walls of the exit channel in the preferred embodiment are parallel in their vertical dimension. The top of the open channel or groove defines a top plane.
Figures 2A through 2D illustrate the use and effect of the sheet of vibrating material. The single unit dose is an agglomerated pellet of medicament powder situated in storage chamber 17, situated in the dose storage substrate 16. The unit dose is protected within the storage chamber by a protective seal. Pressurized air is supplied from a source (not shown) which provides pressurized air in the range of 1 to 60 psi., and a burst of pressurized air is applied to the dose for a period of 10 to 1000 milliseconds.
The pressurized air travels along a passage 22, in the air inlet substrate 18, to impact on and break open the seal containing the single unit dose of drug, and blow the solid dose out through the exit passage 20, in the exit channel substrate 12. Below the dose storage substrate 16, is a vibrating sheet substrate 14, which may be made preferably of 0.0005 to 0.020 in. thick Mylar film or other material appropriately sized and suitable for that purpose. This film is flexible and stretchable. When the blast of pressurized air blows the aggregate's powder downward against the vibrating sheet, the sheet deflects downward into the channel as seen in Figures 2B and 2D, allowing the air and powder mixture to flow through and out of the exit channel. As the flow of air and powder passes over the vibrating sheet, the sheet is induced to vibrate in a whipping or flopping motion as generally indicated in Figures 2B and 2D at a frequency of 10 to 60 KHz. This whipping motion of the vibrating sheet effectively breaks the powder carried by the air flow into smaller and more uniform particles, thus deagglomerating the solid into a fine powder. The particle size achieved is in the range of 2 to 8 microns, which is in the respirable range. Also, the air flow over the Mylar sheet creates a standing wave that has the effect of metering the dose into the air stream.
Figure 3 is an exploded perspective view of a second embodiment of the invention, which is essentially the same in concept as the embodiment of Figure 1, however, the dose storage substrate 34, has sixteen single unit dose storage chambers instead of one. Also, the exit channel substrate 30, has sixteen separate exit channels, one for each dose. In this embodiment the air supply (not shown) is rotatably situated above the air inlet substrate 36. The air supply would be rotated relative to the aligned air inlet 44, dose storage chamber 42 and exit channel 40.
Figure 4 shows the exit channel substrate 30, of Figure 3. The exit channel 40, is shown to be tapered downward as the air flow moves outward from the area below where a unit dose is stored to the exit opening. In addition, the side walls of the channel are vertical and parallel in relation to the flow direction of the channel. However, other embodiments are possible, such as a flat air flow channel, or a channel which has a tapered width in the direction of air flow, or side walls which are tapered or rounded.
Figure 5 shows the alignment of the four elements of Figure 3 with the air inlet 44, positioned directly above the dose storage chamber 42, which in turn is positioned directly over the exit channel 40. The vibrating sheet is between the dose storage and air exit channel.
Figure 6 shows an exploded view of another preferred embodiment, that of a round, multi-dose device which has one exit channel 60, defined in the exit channel substrate 52, and one air inlet passageway 62, defined in the air inlet substrate 58. The dose storage substrate 56, has a plurality of dose storage chambers 64, defined therein. The dose storage substrate is positioned between the vibrating sheet 52, and the air inlet substrate 58. The air inlet passageway 62, is fixed in orientation over the exit channel 60. The individual dose chambers 64, are positioned in the line of the air inlet and exit channel by rotating the dose storage substrate. Thus by the present invention its objects and advantages are realized and although preferred embodiments have been disclosed and described in detail herein, its scope should not be limited thereby rather its scope should be determined by that of the appended claims.

Claims

We Claim:
1. A dry powder inhaler operable with a source of pressurized air, comprising: a- a base substrate having top and front surfaces with an exit channel in the form of a trough defined in said top surface and extending lengthwise to and intersecting said front surface; b- a sheet of flexible material overlying said top surface of said base substrate; c- a dose storage substrate overlying said sheet, said dose storage substrate containing at least one single unit dose of agglomerated medicament powder, said dose storage substrate having a bottom surface adjacent said sheet, at least one chamber defined therein to contain said unit dose, and an opposite top surface, d- an air inlet substrate overlying said dose storage substrate and including at least one passageway for directing pressurized air from a source onto said top surface of said dose storage substrate, said pressurized air forcing said dose from said chamber, said sheet being deformed by said pressurized air downward into said trough, thus providing a discharge passage along said top surface of said sheet, and said dose being driven downward by application of said pressurized air, and forced against said sheet, said sheet vibrating so as to deagglomerate and fluidize said dose and meter the flow of powder through said trough, said dose being carried in a fluidized form through said trough, and said dose exiting from said front surface of said base substrate.
2. An inhaler according to claim 1 wherein said pressurized air is applied at a pressure in the range of 1-100 psi.
3. An inhaler according to claim 1 wherein said pressurized air is applied to said dose for a duration in the range of 10-milliseconds to 1000-milliseconds .
. An inhaler according to claim 2 wherein said pressurized air is applied to said dose for a duration in the range of 10-milliseconds to 1000-milliseconds .
5. An inhaler according to claim 1 wherein said standing wave in said vibrating sheet operates in a frequency range of 10-60 kHz.
6. An inhaler according to claim 1 wherein said sheet comprises a Mylar type film having thickness in the range of 0.0005 to 0.020 inches .
7. An inhaler according to claim 1 which produces a discharge in the form of a plume of dry powder particles sized in the range of 2-8 microns .
8. An inhaler according to claim 1 wherein said unit dose is protected by a protective seal, which is broken upon activation of said pressurized air source.
9. An inhaler according to claim 1 wherein said trough has inlet and exit ends, and said trough is sloped so that it becomes deeper in the direction of its exit end.
10. An inhaler according to claim 9 wherein said trough has generally parallel side walls.
11. An inhaler according to claim 1 wherein: a said base substrate has a plurality of said troughs spaced apart from each other, b said sheet overlies all of said troughs, c said dose storage substrate contains a plurality of single unit doses, each of said unit doses being situated within chambers defined in said dose storage substrate, each of said chambers being situated so as to align with and overlie one of said troughs, and d said air inlet substrate having at least one passageway laterally movable to overlie and be directed selectively to each of said stored single unit doses, said pressurized air being applicable via said air inlet substrate selectively to each of said doses to be directed as a plume of powder from its respective exit channel .
12. An inhaler according to claim 1 wherein: a said base has a single exit canal comprising a trough, b said sheet overlies said trough, c said air inlet substrate has at least one passageway, said passageway being fixed in a position over said trough, d said dose storage substrate contains a plurality of single unit doses, said dose storage substrate capable of being rotatably positioned and aligned over said trough and beneath said air inlet passageway, said pressurized air being applicable via said passageway selectively to each of said doses to be directed as a plume of powder from said trough.
13. A method of deagglomerizing a dose of agglomerated dry powder in an inhaler where pressurized air is applied to said dose, blowing it through an exit channel having inlet and exit ends, comprising the steps: a providing a sheet of vibratable material in said exit channel, extending generally from said inlet to said exit end, b directing said pressurized air carrying said dry powder to flow along the surface of said sheet in said exit channel thereby causing said sheet to vibrate and create a standing wave in said sheet, whereby said standing wave helps to deagglomerize and fluidize said powder in said pressurized air flow.
14. A method according to claim 13 wherein said pressurized air is applied at a pressure in the range of 1-100 psi.
15. A method according to claim 13 wherein said pressurized air is applied for a duration in the range of 10-milliseconds to 1000- milliseconds.
16. A method according to claim 13 wherein said vibrating sheet operates in a frequency range of 10-60 kHz.
17. A method according to claim 13 wherein said deagglomerated dry powder has particles sized in the range of 2-8 microns.
EP01992208A 2001-01-08 2001-12-18 Dry powder inhaler Expired - Lifetime EP1351734B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CY20081100056T CY1108525T1 (en) 2001-01-08 2008-01-15 DRY POWDER FUEL

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US756313 2001-01-08
US09/756,313 US6626173B2 (en) 2001-01-08 2001-01-08 Dry powder inhaler
PCT/US2001/049409 WO2002053215A2 (en) 2001-01-08 2001-12-18 Dry powder inhaler

Publications (2)

Publication Number Publication Date
EP1351734A2 true EP1351734A2 (en) 2003-10-15
EP1351734B1 EP1351734B1 (en) 2007-11-14

Family

ID=25042937

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01992208A Expired - Lifetime EP1351734B1 (en) 2001-01-08 2001-12-18 Dry powder inhaler

Country Status (12)

Country Link
US (1) US6626173B2 (en)
EP (1) EP1351734B1 (en)
JP (1) JP4021323B2 (en)
AT (1) ATE378083T1 (en)
AU (1) AU2002232674B2 (en)
CA (1) CA2433799C (en)
CY (1) CY1108525T1 (en)
DE (1) DE60131453T2 (en)
DK (1) DK1351734T3 (en)
ES (1) ES2294044T3 (en)
PT (1) PT1351734E (en)
WO (1) WO2002053215A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20050147566A1 (en) * 2002-03-12 2005-07-07 Scott Fleming Site specific delivery of co-administered drugs via inhalation
ES2300568T3 (en) 2002-03-20 2008-06-16 Mannkind Corporation INHALATION APPARATUS
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US8641715B2 (en) 2002-05-31 2014-02-04 Vidacare Corporation Manual intraosseous device
US10973545B2 (en) 2002-05-31 2021-04-13 Teleflex Life Sciences Limited Powered drivers, intraosseous devices and methods to access bone marrow
US11337728B2 (en) 2002-05-31 2022-05-24 Teleflex Life Sciences Limited Powered drivers, intraosseous devices and methods to access bone marrow
CA2485904C (en) 2002-05-31 2013-05-21 Vidacare Corporation Apparatus and method to access the bone marrow
US9072543B2 (en) 2002-05-31 2015-07-07 Vidacare LLC Vascular access kits and methods
US8668698B2 (en) 2002-05-31 2014-03-11 Vidacare Corporation Assembly for coupling powered driver with intraosseous device
US10973532B2 (en) 2002-05-31 2021-04-13 Teleflex Life Sciences Limited Powered drivers, intraosseous devices and methods to access bone marrow
US9504477B2 (en) 2003-05-30 2016-11-29 Vidacare LLC Powered driver
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
WO2005041848A2 (en) * 2003-10-27 2005-05-12 Oriel Therapeutics, Inc. Dry powder drug containment system packages with tabs, inhalers and associated methods
US7861712B2 (en) * 2004-04-23 2011-01-04 Manta Product Development Sealed capsule including an integrated puncturing mechanism
MX2007001903A (en) 2004-08-20 2007-08-02 Mannkind Corp Catalysis of diketopiperazine synthesis.
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
WO2006037636A2 (en) 2004-10-06 2006-04-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing powder
JP2006130143A (en) * 2004-11-08 2006-05-25 Hitachi Ltd Inhalation administration device and medicine cartridge
GB0500677D0 (en) * 2005-01-14 2005-02-23 Britannia Pharmaceuticals Ltd Dry powder inhaler
KR101488403B1 (en) 2005-05-18 2015-02-04 엠펙스 파마슈티컬즈, 인코포레이티드 Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP5465878B2 (en) 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP1986722B1 (en) 2006-01-31 2018-10-24 Oriel Therapeutics, Inc. Dry powder inhalers having spiral travel paths for microcartridges with dry powder
CN104383546B (en) 2006-02-22 2021-03-02 曼金德公司 Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent
US8127763B2 (en) * 2006-03-03 2012-03-06 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
JP5188991B2 (en) * 2006-03-03 2013-04-24 エスティーシー．ユーエヌエム Dry powder inhaler with aeroelastic distribution mechanism
CN101489613A (en) * 2006-07-14 2009-07-22 阿斯利康(瑞典)有限公司 Inhalation system and delivery device for the administration of a drug in the form of dry powder
US8944069B2 (en) 2006-09-12 2015-02-03 Vidacare Corporation Assemblies for coupling intraosseous (IO) devices to powered drivers
DE102006044756A1 (en) * 2006-09-20 2008-04-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg inhaler
WO2008091355A2 (en) * 2007-01-24 2008-07-31 Breathe Pharmaceuticals, Inc. Drug transfer device
US7899528B2 (en) * 2007-05-17 2011-03-01 Vidacare Corporation Method and apparatus to monitor patients and treat with intraosseous fluids
EP2042208A1 (en) * 2007-09-25 2009-04-01 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device
US8311914B2 (en) * 2007-10-30 2012-11-13 Visa U.S.A. Inc. Payment entity for account payables processing using multiple payment methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (en) 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
WO2010036839A2 (en) 2008-09-26 2010-04-01 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
CN102159269B (en) 2008-09-26 2014-05-07 奥里尔治疗公司 Dry powder inhalers with dual piercing members and related devices and methods
ES2550309T3 (en) 2008-09-26 2015-11-06 Oriel Therapeutics, Inc. Inhaler mechanisms with radially predisposed perforators and related methods
WO2010039201A2 (en) 2008-09-30 2010-04-08 Oriel Therapeutics, Inc. Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods
MX2011003245A (en) 2008-10-01 2011-04-26 Oriel Therapeutics Inc Dry powder inhalers with rotating piercing mechanisms and related devices and methods.
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
PL2346509T3 (en) 2008-10-07 2021-03-08 Horizon Orphan Llc Inhalation of levofloxacin for reducing lung inflammation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
MX353288B (en) 2009-09-04 2018-01-08 Raptor Pharmaceuticals Inc Use of aerosolized levofloxacin for treating cystic fibrosis.
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US9492625B2 (en) 2009-11-12 2016-11-15 Stc.Unm Dry powder inhaler with flutter dispersion member
AU2010249272C1 (en) * 2009-12-18 2014-07-17 Bissell Inc. Dry vacuum cleaner with spot cleaning
WO2011080761A1 (en) 2009-12-30 2011-07-07 Thirumalai Anadampillai Aparna An improved dry powder inhaler
WO2011085022A1 (en) 2010-01-05 2011-07-14 Microdose Therapeutx, Inc. Inhalation device and method
USD641076S1 (en) 2010-03-26 2011-07-05 Oriel Therapeutics, Inc. Dry powder inhaler
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
ES2913095T3 (en) 2011-01-31 2022-05-31 Avalyn Pharma Inc Aerosolized pirfenidone and pyridone analog compounds and uses thereof
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
WO2013167429A1 (en) * 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Atomizer
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR112016000937A8 (en) 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
CN105517610A (en) 2013-09-04 2016-04-20 3M创新有限公司 Dry-powder inhaler and method
WO2015106150A1 (en) 2014-01-10 2015-07-16 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2972826C (en) 2015-01-14 2023-09-12 Respira Therapeutics, Inc. Powder dispersion methods and devices
PT3519025T (en) * 2016-09-30 2023-03-03 De Motu Cordis Pty Ltd Delivery device and associated methods of use
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1123827A (en) 1965-06-19 1968-08-14 Nick Nikodem Urbanowicz Spray producer
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
AU684754B2 (en) 1993-03-03 1998-01-08 Glaxo Wellcome Inc. Dry powder inhalator medicament carrier
GB9312984D0 (en) 1993-06-23 1993-08-04 Bespak Plc Atomising dispenser
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
FR2718968B1 (en) 1994-04-20 1996-07-26 Valois Sa Insert delimiting a metering chamber of an inhaler.
SE9502799D0 (en) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
US6026809A (en) 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
US5694920A (en) 1996-01-25 1997-12-09 Abrams; Andrew L. Inhalation device
FR2747311B1 (en) 1996-04-10 1998-08-14 Pf Medicament POWDER AND COMPRESSED AIR INHALER
SE9700422D0 (en) 1997-02-07 1997-02-07 Astra Ab Single dose inhaler II
US6006747A (en) 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6237590B1 (en) * 1997-09-18 2001-05-29 Delsys Pharmaceutical Corporation Dry powder delivery system apparatus
US6003512A (en) 1997-11-13 1999-12-21 Lovelace Respiratory Research Institute Dust gun-aerosol generator and generation
US6378518B1 (en) * 1998-10-30 2002-04-30 Richard George Miekka Method for producing uniform small doses of finely divided substances
GB9905538D0 (en) 1999-03-10 1999-05-05 Glaxo Group Ltd A device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02053215A2 *

Also Published As

Publication number Publication date
US20020088462A1 (en) 2002-07-11
WO2002053215A3 (en) 2003-02-06
EP1351734B1 (en) 2007-11-14
JP2004527271A (en) 2004-09-09
DK1351734T3 (en) 2008-02-11
ES2294044T3 (en) 2008-04-01
WO2002053215A2 (en) 2002-07-11
JP4021323B2 (en) 2007-12-12
CY1108525T1 (en) 2014-04-09
DE60131453T2 (en) 2008-09-04
ATE378083T1 (en) 2007-11-15
AU2002232674B2 (en) 2005-04-28
PT1351734E (en) 2007-12-21
US6626173B2 (en) 2003-09-30
CA2433799C (en) 2008-09-16
CA2433799A1 (en) 2002-07-11
DE60131453D1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AU2002232674B2 (en) Dry powder inhaler
AU2002232674A1 (en) Dry powder inhaler
US6779520B2 (en) Breath actuated dry powder inhaler
EP1166812B1 (en) Packaging and delivery of pharmaceuticals and drugs
EP2277577B1 (en) Dispensing device for dispensing powder
EP1328310B1 (en) Dry powder inhaler
US7334577B2 (en) Synthetic jet based medicament delivery method and apparatus
EP1083952B1 (en) Device for delivery of pharmaceuticals and drugs
US20100154794A1 (en) Inhaler Flow Channel
EP1563864A2 (en) Inhalation device
EP3171920B1 (en) Dry powder nebulizer
US20170209655A1 (en) Dry powder medicament de-agglomerator
US20070101991A1 (en) Optimizing release of dry medicament powder

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030708

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KOS LIFE SCIENCES, INC.

17Q First examination report despatched

Effective date: 20050422

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KOS LIFE SCIENCES, INC.

17Q First examination report despatched

Effective date: 20050422

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20071211

REF Corresponds to:

Ref document number: 60131453

Country of ref document: DE

Date of ref document: 20071227

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070403833

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2294044

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071114

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20101124

Year of fee payment: 10

Ref country code: FR

Payment date: 20101203

Year of fee payment: 10

Ref country code: DK

Payment date: 20101123

Year of fee payment: 10

Ref country code: AT

Payment date: 20101122

Year of fee payment: 10

Ref country code: IE

Payment date: 20101126

Year of fee payment: 10

Ref country code: MC

Payment date: 20101129

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20101129

Year of fee payment: 10

Ref country code: CH

Payment date: 20101026

Year of fee payment: 10

Ref country code: LU

Payment date: 20101216

Year of fee payment: 10

Ref country code: FI

Payment date: 20101203

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20101129

Year of fee payment: 10

Ref country code: GB

Payment date: 20101123

Year of fee payment: 10

Ref country code: SE

Payment date: 20101122

Year of fee payment: 10

Ref country code: IT

Payment date: 20101211

Year of fee payment: 10

Ref country code: GR

Payment date: 20101126

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20101119

Year of fee payment: 10

Ref country code: DE

Payment date: 20101230

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20101213

Year of fee payment: 10

Ref country code: ES

Payment date: 20101215

Year of fee payment: 10

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120618

BERE Be: lapsed

Owner name: KOS LIFE SCIENCES, INC.

Effective date: 20111231

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120701

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20111218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120618

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20070403833

Country of ref document: GR

Effective date: 20120704

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60131453

Country of ref document: DE

Effective date: 20120703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120703

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111219

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120704

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 378083

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111218

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120102

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120701

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111218

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111219